DNA RNA and Cells

5 June 2016

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting

5 June 2016

Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL

4 June 2016

Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data

4 June 2016

Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO

4 June 2016

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

2 June 2016

Kiadis Pharma Announces Its Decision to File for Marketing Authorization with the European Medicines Agency (EMA) for ATIR101™ in Blood Cancers

2 June 2016

The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si

2 June 2016

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer

2 June 2016

Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)

31 May 2016

StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

31 May 2016

Clinical Study in UK to Evaluate ReGenerCell(TM) for Diabetic Foot Ulcer Treatment

30 May 2016

DCGI Gives Limited Approval to Market FIRST Allogeneic Cell Therapy Product in India Stempeutics puts India on the ‘World map of Regenerative Medicine’

27 May 2016

TxCell obtains authorization from European regulatory authorities to restart Ovasave(R) Phase IIb clinical trial

27 May 2016

Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program

26 May 2016

Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial

25 May 2016

Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1

25 May 2016

Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)

25 May 2016

AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND

24 May 2016

Vital Therapies Enrolls First Subject in VTL-308

19 May 2016

Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016

19 May 2016

ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

17 May 2016

Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

17 May 2016

NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Moonshot 2020 Initiative

16 May 2016

Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

14 May 2016

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)

12 May 2016

Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates

8 May 2016

AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1

8 May 2016

Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered Hemophilia A Program at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

6 May 2016

Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results

6 May 2016

Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Report Package: “Drug the Undruggable” Technologies

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

TL1A Inhibitor Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

TROP-2-Targeted Immunotherapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics